One injection (case 744) involved the retrochiasmatic area and, to a lesser degree, the ventral extent of the anterior hypothalamic nucleus, but it completely avoided the ventromedial hypothalamic nucleus. The two injections in the anterior hypothalamic nucleus (cases 770 and 771) involved primarily the central part. Finally, two injections were centered in

the ventromedial hypothalamic nucleus, the rostroventral one (case 746) included mainly the anterior, central and ventrolateral parts and the caudodorsal Tanespimycin manufacturer one (case 747), the central and dorsomedial parts. The former injection also encroached peripherally on the retrochiasmatic area, and the latter on the dorsomedial hypothalamic nucleus. In general, the control experiments fully ZD1839 cell line confirmed the anterograde tracing results of the MeAV case 565. The retrograde labeling in the Me is almost exclusively ipsilateral, except after injections in the ventromedial hypothalamic nucleus where an expressive contralateral labeling is present in ventral Me parts. A dense cluster of vividly labeled cells outlined the MeAV after injections in the lateral amygdaloid nucleus (Figs. 9A1, 10A), posterior basomedial amygdaloid nucleus (Figs. 9A2, 10B), amygdalostriatal transition area/lateral central nucleus (Figs. 9A3, 10C) and

ventromedial hypothalamic nucleus (Figs. 10D, 11A4). A moderately dense retrograde labeling was observed in the MeAV (up to 12 labeled cells per section) Thalidomide after injections in the retrochiasmatic area (Fig. 11A3), anterior hypothalamic

nucleus and posterior part of the medial BST (Figs. 10E, 11A1), and a more modest one, after an injection in the anterior part of the medial BST. The substantial retrograde labeling found in the MeAV after injections in the anterior hypothalamic nucleus contrasts with PHA-L observations indicating that this nucleus contains MeAV fibers en route to more posterior targets, being itself sparingly innervated. Having in mind the possibility of an uptake of FG by fibers-of-passage (e.g., Dado et al., 1990) and of a minimal spillover of FG into adjacent parts of the ventromedial hypothalamic nucleus, one should tentatively conclude that if MeAV projections to the anterior hypothalamic nucleus do indeed exist, they are rather modest. Very few retrogradely labeled cells (up to 3 per section) were seen in the MeAV in the three cases with injections centered the medial preoptic nucleus (Figs. 10F, 11A2–D2). For comparative purpose, the retrograde labeling in the other parts of the Me will be briefly described in these FG cases (Fig. 9 and Fig. 11). In Ce/ASt case 740, a rather modest retrograde labeling was observed in the MeAD, whereas the MePV and MePD were devoid of labeling (Fig. 9A3, B3). In all the other FG cases, retrogradely labeled cells were distributed throughout the MeAD and MePV (Fig. 9 and Fig.